MK 5720
Alternative Names: MK-5720Latest Information Update: 10 Apr 2024
At a glance
- Originator Merck Sharp & Dohme
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 15 Feb 2024 Merck Sharp and Dohme completes a phase I MK-5720-001 trial in Schizophrenia in USA (IM, Injection) (NCT05953740)
- 15 Sep 2023 Phase-I clinical trials in Schizophrenia in USA (IM) (NCT05953740)
- 27 Jul 2023 Merck Sharp and Dohme plans a phase I MK-5720-001 trial for Schizophrenia in August 2023 (IM, Injection) (NCT05953740)